About ruxolitinib phosphate equivalent to ruxolitinib
JAK1/JAK2 inhibitor
Used for
- Myelofibrosis
- Polycythemia vera after inadequate response or intolerance to hydroxyurea
- Graft-versus-host disease in eligible patients
Usual adult dose
Usually 15–20 mg twice daily for myelofibrosis; 10 mg twice daily for polycythemia vera or graft-versus-host disease. Dose depends on blood counts and indication.
Usual dose in children
For graft-versus-host disease, typically 5 mg twice daily from age 12; specialist-directed dosing and monitoring are required.
Common side effects
- Low platelet, red blood cell, or white blood cell counts
- Bruising or bleeding
- Infections, including shingles
- Dizziness, headache, or raised cholesterol
Important warnings
- Can cause serious infections; screen for tuberculosis and monitor for infection.
- Blood counts require regular monitoring; severe cytopenias may need dose changes.
- May increase risk of certain cancers, major cardiovascular events, and blood clots.
- Do not stop suddenly without medical guidance; symptoms may worsen.
Pregnancy
May harm an unborn baby; pregnancy should be avoided during treatment and for one week after the final dose.
Breastfeeding
Avoid breastfeeding during treatment and for two weeks after the final dose.
Interactions
- Strong CYP3A4 inhibitors, such as ketoconazole, can raise ruxolitinib levels.
- Fluconazole can raise levels; dose adjustment may be needed.
- Rifampin and other strong CYP3A4 inducers can lower levels.
- Other medicines that suppress the immune system may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.